Gosselies, Belgium – Évry, France July 9th, 2020
This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of both companies would enable to offer a complete solution that combines oncology laboratory testing and software solutions which will benefit the treatment of patients with advanced cancer.
Scientific Application Note
When is the optimal time for biomarker testing in the patient pathway?
The two key questions addressed by biomarker testing are (1) is there an approved therapy available, and (2) is there a clinical trial option. Currently, a quarter of patients with advanced cancer will potentially benefit from...
